Immix Biopharma Announces NXC-201 Clinical Data Abstract Accepted For Oral Presentation At 27th Annual Meeting Of ASGCT
Portfolio Pulse from Benzinga Newsdesk
Immix Biopharma announced that an abstract on clinical data for its next-generation CAR-T therapy, NXC-201, targeting relapsed/refractory AL amyloidosis, has been accepted for oral presentation at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in Baltimore, scheduled for May 7-11, 2024.
April 15, 2024 | 1:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immix Biopharma's announcement about the acceptance of NXC-201 clinical data abstract for oral presentation at ASGCT 2024 highlights progress in its pipeline.
The acceptance of Immix Biopharma's NXC-201 clinical data for presentation at a prestigious conference like ASGCT is a positive indicator of the therapy's potential and the company's progress. This could lead to increased investor interest and potentially positive movement in IMMX's stock price in the short term, as it validates the company's research and development efforts.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100